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2SUMMARY
The ryanodine receptor plays a crucial role in skeletal muscle excitation-contraction
coupling by releasing calcium required for muscle contraction from the sarcoplasmic reticulum.
At least three phenotypes associated with more than 100 RYR1 mutations have been identified; in
order to elucidate possible pathophysiological mechanisms of RYR1 mutations linked to
neuromuscular disorders, it is essential to define the mutation class by studying the functional
properties of channels harboring clinically relevant amino acid substitutions. In the present report
we investigated the functional effect of the c.7304G>T RYR1 substitution (p.Arg2434Leu)
identified in a patient affected by central core disease. Both parents were heterozygous for the
substitution while the affected proband was homozygous. We characterized Ca2+ homeostasis in
myoD transduced myotubes from controls, the heterozygous parents and the homozygous
proband expressing the endogenous mutation. We also expressed the recombinant mutated
channel in heterologous cells and characterized its [3H]ryanodine binding and single channel
properties. Our results show that the presence of the p.Arg2434Leu substitution either at the
homozygous or heterozygous state, affects neither the resting [Ca2+], nor the sensitivity of the
ryanodine receptor to pharmacological activators, but rather reduces KCl-induced Ca2+ release
via the voltage sensing dihydropyridine receptor.
3INTRODUCTION
The ryanodine receptor (RyR) ion channels are large protein complexes composed of four
RyR 560 kDa peptides and various associated proteins with a total molecular weight of greater
than 2,500 kDa. They play a crucial role in skeletal muscle excitation-contraction coupling by
releasing calcium ions required for muscle contraction from the sarcoplasmic reticulum [1,2].
Mutations in the skeletal muscle isoform of the ryanodine receptor, which is encoded by a gene
located on human chromosome 19, are associated with at least three neuromuscular disorders and
may be linked to certain forms of heat stroke [3-6]. Four phenotypes associated with more than
100 RYR1 mutations have been identified to date; most commonly, dominant mutations have
been found to associate with typical central core disease (CCD; OMIM # 117000) and the
malignant hyperthermia susceptibility trait (MHS) (MH; OMIM #145600) [3,4], whereas few
recessive mutations have been identified in patients affected by clinically distinct forms of multi-
minicore disease (MmD) (MmD; OMIM # 602771) and forms of CCD with unusual or more
severe presentations [7-10]. In most cases, dominant RYR1 mutations linked to CCD localize to
the COOH-terminal domain of the channel, containing the transmembrane and pore-forming
domains of the RyR1 channel, whereas MHS-linked mutations were initially mapped to hot spot
areas within the NH2 and central RyR domains; however, more recently identified MHS-linked
mutations seem to be distributed throughout the entire RYR1 coding region.
It appears that RYR1 mutations result in 4 different channel defects: (i) one class of
mutations (mostly associated with MHS phenotype) cause Ca2+ channels to become
hypersensitive to membrane depolarisation and pharmacological activation; (ii) a second class of
mutations render the Ca2+ channel unable to conduct Ca2+ [11], (iii) a third class of mutations
uncouples RyR1 from the voltage sensor (mutation class 2 and 3 are mostly associated to CCD
4and have not been clearly distinguished);  (iv) the forth class of mutations (found in hemyzygous
MmD patients) results in protein Ca2+ channel instability which ultimately leads to a decrease of
the expression level within muscle [9, 12]. In order to elucidate possible pathophysiological
mechanisms of neuromuscular disorders linked to RYR1 mutation, it is essential to define the
mutation class by studying the functional properties of channels harbouring clinically relevant
amino acid substitutions.
One of the first mutations identified in RYR1 associated with the CCD phenotype, was
the heterozygous A>G7302 substitution, leading to the p.Arg2434His mutation [13]. This
substitution was also identified at the heterozygous level in some patients who were classified as
MHS by the in vitro contracture test [14-16]. Functional analysis indeed confirmed that when
expressed as a recombinant channel in heterologous HEK293 cells, the presence of this mutation
led to a shift in sensitivity to both caffeine and halothane [17|. A similar p.Arg2435Leu
substitution was also identified at the heterozygous state in some MHS and CCD families [14,
15,18].
Recently, we characterized a large cohort of patients with clinical, histological and
muscle imaging features suggestive of RYR1 involvement and identified nine novel mutations,
including the homozygous substitution c.7304G>T leading to a p.Arg2435Leu mutation in a
patient affected by CCD [19]. Because in some patients affected by core myopathies,
monoallelic expression of the mutation has been found in muscles [9, 19, 20], we undertook a
more detailed investigation of the patient and her family members. Both parents were
heterozygous for the p.Arg2435Leu substitution while the affected proband was homozygous,
confirming the classical Mendelian inheritance of this mutation. Since both parents were
unaffected, we reasoned that the genotype-phenotype correlation might be linked to the presence
5of the mutation at the homozygous state. In the present study we (i) characterized Ca2+
homeostasis in MyoD transduced myotubes from controls, heterozygous parents and the
homozygous proband expressing the endogenous mutation and (ii) expressed the recombinant
mutated channel in heterologous cells and characterized its [3H]Ryanodine binding
characteristics and single channel properties. Our results show that the presence of the
p.Arg2434Leu substitution either at the homozygous or heterozygous state, affects neither
resting [Ca2+], nor the sensitivity of the ryanodine receptor to pharmacological activators, but
rather reduces Ca2+ release induced by activation of the voltage sensor by KCl membrane
depolarization.
6METHODS
Patient phenotype and family history
The patient is currently a 15 years old girl who presented, following an unremarkable perinatal
history and normal early normal development, at the age of 3-4 years with toewalking and a
hyperlordotic posture. At age 6 years she was operated for contractures of the Achilles tendons
and the muscle biopsy performed at the time, was consistent with central core disease.
Subsequently, in addition to her hyperlordosis, she developed a moderate scoliosis and bilateral
scapular winging; on examination she had a mild Gowers’ sign but was able to jump. Her CK
was 700 IU/l. There was no known consanguinity although both parents originate from the same
town in Italy. There was no history of MH in the parents (the mother has undergone anaesthesia
on two separate occasions) or in other family members; no MH test has ever been done in her
family but both parents are aware that they both have moderately increased CK (300 IU/l).
Genetic investigation [19] showed that the parents carried the heterozygous substitution
c.7304G>T in exon 45 and that the patient was homozygous for the substitution. Screening of the
entire RYR1 cDNA did not reveal the presence of any other nucleotide changes.
MyoD transduced fibroblasts
It was not possible to obtain myotubes from the muscle biopsies but primary skin fibroblast
cultures were established from the proband and unaffected parents. Functional studies were
performed on fibroblasts transduced with MyoD-encoding adenovirus in order to achieve
myogenic conversion, as previously described [12].
Intracellular calcium measurements:
Changes in the intracellular Ca2+ concentration, [Ca2+]i, of myotubes were monitored with the
fluorescent Ca2+ indicator fura-2 at the single cell level by digital imaging microscopy as
7previously described [12,21]. Individual cells were stimulated with a 12-way 100 mm diameter
quartz micromanifold computer controlled microperfuser (ALA Scientific). On-line (340 nm,
380 nm and ratio) measurements were recorded using a fluorescent Axiovert S100 TV inverted
microscope (Carl Zeiss GmbH, Jena, Germany) equipped with a 20x water-immersion FLUAR
objective (0.17 NA), filters (BP 340/380, FT 425, BP 500/530). Cells were analyzed using an
Openlab imaging system and the average pixel value for each cell was measured at excitation
wavelengths of 340 and 380 nm.
Construction of mutant cDNAs and Expression of wild-type and mutant RyR1 proteins in
HEK293 cells:
Base changes of rabbit RyR1 cDNA were performed by Pfu-turbo polymerase-based chain
reaction using mutagenic oligonucleotides and the QuikChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA) as described previously [22]. Briefly, a fragment of RyR1 cDNA
(XhoI-BbrPI (6598-7692)), subcloned into cloning vector, served as a template for PCR. The
mutated fragment amplified by PCR was confirmed by DNA sequencing and cloned back into
the original position by standard cloning techniques. Finally, expression plasmids for full-length
RyR1 with the mutation were constructed by ligating three RyR1 fragments (ClaI/XhoI
(polylinker-6598), XhoI/EcoRI (6598-11767), EcoRI/XbaI (11767-polylinker)) and pCMV5
(ClaI/XbaI) expression vector. Nucleotide numbering is as described previously [23].
Wild-type RyR1 and mutant cDNAs were transiently expressed in HEK293 cells
transfected with FuGENE 6 according to the manufacturer’s instructions. Cells were maintained
at 37°C and 5% CO2 in high glucose Dulbecco’s modified eagle medium containing 10% fetal
bovine serum and plated the day before transfection. For each 10 cm tissue culture dish, 3.5 µg
of cDNA was used. Cells were harvested 48 h after transfection. Crude membrane fractions and
8proteoliposomes containing the purified RyR1s were prepared in presence of protease inhibitors
as described [22].
[3H]Ryanodine Binding   
 [3H]Ryanodine binding experiments were performed with crude membrane fractions prepared
from HEK 293 cells as previously described [22]. Unless otherwise indicated, membranes were
incubated with 3 nM [3H]ryanodine in 20 mM imidazole, pH 7.0, 0.15 M sucrose, 250 mM KCl,
5 mM Mg2+, 5mM AMPPCP (a nonhydrolyzable ATP analogue), 5 mM reduced glutathione,
protease inhibitors, and indicated Ca2+ and caffeine concentrations. Nonspecific binding was
determined using a 1000-2000 fold excess of unlabeled ryanodine. After 20 h, samples were
diluted with 8 volumes of ice-cold water and placed on Whatman GF/B filters preincubated with
2% polyethyleneimine in water. Filters were washed with three 5 ml ice-cold 100 mM KCl, 1
mM KPipes, pH 7.0 solution. The radioactivity remaining with the filters was determined by
liquid scintillation counting to obtain bound [3H]ryanodine.
Bmax values of [3H]ryanodine binding were determined by incubating membranes
for 4 h at 24oC with a saturating concentration of [3H]ryanodine (30 nM) in 20 mM imidazole,
pH 7.0, 0.6 M KCl, 0.15 M sucrose, 1 mM glutathione (oxidized), protease inhibitors, and 100
µM Ca2+. Specific binding was determined as described above.
Single channel recordings
Single channel measurements were performed using planar lipid bilayers containing a 5:3:2
mixture of bovine brain phosphatidylethanolamine, phosphatidylserine, and phosphatidylcholine
(25 mg of total phospholipid/ml n-decane as previously described [11]. Proteoliposomes
containing the purified recombinant RyR1s were added to the cis (SR cytosolic side) chamber of
a bilayer apparatus and fused in the presence of an osmotic gradient (250 mM cis KCl/20 mM
trans KCl in 20 mM KHepes, pH 7.4, 2 µM Ca2+). After the appearance of channel activity, trans
9(SR lumenal side) KCl concentration was increased to 250 mM to prevent further fusion of
proteoliposomes. To determine K+ and Ca2+ conductances and permeability ratios, single channel
activities were recorded in symLeurical 250 mM KCl solution before and after addition of 10
mM Ca2+ to the trans side, and analyzed as described [11].
Statistical analysis
Statistical analysis was performed using the Student’s t test for paired samples or using
ANOVA when more than two groups were compared. Origin computer program (Microcal
Software, Inc., Northampton, MA, USA) was used for statistical analysis and dose response
curve generation.
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RESULTS AND DISCUSSION
In order to assess the functional effect of the p.Arg2435Leu mutation, we used myotubes
derived from MyoD transduced fibroblasts obtained from controls, the heterozygous parents and
the homozygous patient. We have previously shown that such myotubes express a functional
RyR1 ion channel and represent a valid model to assess the effects of RyR1 mutations on stored
Ca2+ release [12]. We determined the resting [Ca2+], the dose dependent-sensitivity of the
myotubes to caffeine and 4-chloro-m-cresol and the peak Ca2+ release from fura-2 laded
myotubes, since we have previously demonstrated that most pathogenic RYR1 mutations can
alter any of these parameters [12,21]. Figures 1A and B show that the presence of the
p.Ar2435Leu substitution at the heterozygous or homozygous state did not increase the
sensitivity of Ca2+ release either to caffeine or to 4-chloro-m-cresol. The presence of the
mutation at the homozygous state did however significantly diminish the peak of Ca2+ release by
caffeine.
To verify whether the functional coupling of the RyR1 with the dihydropyridine receptor
(DHPR) voltage sensor was affected by the mutation, we activated the RyR1 via the DHPR,
using the KCl-induced membrane depolarisation protocol. As shown in Fig.1C the response of
myotubes carrying the p.Arg2435Leu substitution to a maximally activating KCl concentration
(100 mM) was reduced by more than 50% in cells harbouring the mutation, compared to cells
from control individuals. Our results are in partial support with the data of Dirksen and Avila,
who showed that in dyspedic myotubes transduced with the RYR1 cDNA encoding the
p.Arg2435Leu mutation, the maximal voltage-activated Ca2+ release was reduced [24]. However,
at variance with their data, we found that the presence of the p.Arg2435Leu mutation does not
affect the resting [Ca2+].
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To more directly analyse the functional consequences of the p.Arg2435Leu
mutation, HEK293 cells were transfected with the wild type or mutated RYR1 cDNAs. Crude
membrane fractions were prepared from the cells, and the sensitivity of recombinant channels to
caffeine and Ca2+ was determined. To simulate in vivo conditions, experiments were done in
presence of 5 mM Mg2+, 5mM AMPPCP (a nonhydrolyzable ATP analogue), and 5 mM reduced
glutathione. As shown in figure 2A, the p.Arg2435Leu substitution causes a small but significant
increase in [3H]ryanodine binding at low (µM) and high (mM) calcium concentrations. Caffeine
sensitivity was determined at 0.15 µM free Ca2+. In accordance with increased [3H]ryanodine
binding at low Ca2+ concentrations, mutant channels exhibited an increased level of
[3H]ryanodine binding in the presence of 1-5 mM caffeine compared to WT (Fig. 2B). Similar
[3H]ryanodine binding levels were obtained at 10 and 20 mM caffeine.  We conclude that the
p.Arg2435Leu substitution increases the sensitivity of RyR1 to low and high concentrations of
Ca2+ compared to WT without a noticeable shift in sensitivity to caffeine.
In order to gain insight into the biophysical properties of the channels harbouring the
p.Arg2435Leu substitution, the single channel properties of recombinant wild type and mutated
RyR1s were compared. Figures 3A and C show that mutant channels exhibited some small (not
significant) increases in channel activity at low (0.1 µM) and high (10 mM) free Ca2+; however,
none of these were statistically significant. The p.Arg2435Leu substitution did not significantly
alter the K+ conductance and Ca2+ over K+ permeability ratio of mutant channels compared to
WT (Fig. 3B).
From the results of this and other investigations, it appears that the impact of the
substitution of Arg2435 is quite complex and may relate to several variables, including the
genotype of the carrier (homozygous vs heterozygous) and the actual substituted residue. In fact,
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several groups have reported the presence of a similar but not identical dominant p.Arg2434His
mutation in CCD/MH families [13-16]. The biochemical properties of amino acid residues Leu,
His and Arg are quite diverse: the former is a non-polar, non-charged residue, the latter carries a
positively charged polar side chain, while His is a polar residue whose charge is strongly
influenced by pH, being approximately 50% positively charged at physiological pH [25]. Thus
the substitution of His or Leu for Arg, most likely has a different effect on the channel’s function
and we would like to emphasize that the results of the present investigation can only be viewed
in light of the p.Arg2435Leu substitution.
In skeletal muscle, the DHPR is present on the transverse tubular membrane where it
serves as a voltage sensor; the II-III loop of the α1 subunit (Cav1.1) of the DHPR physically
interacts with RyR1s which are located on the terminal cisternae of SR [26-28]. After sensing an
action potential, the DHPR undergoes a conformational change whereby bi-directional signalling
with the RyR is activated, leading to release of Ca2+ from the SR [29-31]. The domains involved
in the DHPR-RyR1 interaction have been identified; one of these (R10) lies between residues
1635 and 2636 of the RyR1 and is important for skeletal type excitation-contraction coupling
[30, 32]. While on the DHPR, the region lying between residues 720-765 of the Cav1.1 is critical
for skeletal excitation contraction-coupling [30,33]; the latter region contains a stretch of charged
residues and has a net negative charge (13 negatively charged residues and 3 positively charged
residues). If residue p.Arg2435 is part of the interacting domain between RyR1 and Cav1.1, it is
plausible that replacement of a positively charged residue within the RyR1/Cav1.1 interaction
site  may affect the electrostatic interaction between the two proteins, leading to a less efficient
functional coupling and reduced Ca2+ release. Our hypothesis is that the pathophysiological
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mechanism of the p.Arg2435 substitution may be associated with attenuated orthograde coupling
between Cav1.1 and RyR1.
As to the presence of the heterozygous mutation in MH individuals, our results do not
show the typical increase in sensitivity to caffeine and 4-chloro-m-cresol observed in association
with p.Arg2435His expression in HEK293 cells [17] or an increased resting [Ca2+], typically
observed in many cells expressing MHS-linked mutations [21, 34]. In this context, our results are
at variance with those of Dirksen and Avila [24] as they observed an increase in resting [Ca2+],
whereas we did not. This difference may be linked to differences in the experimental models. We
measured the activity of endogenously expressed RyR1s, whereas Dirksen and Avila over-
expressed the mutated RYR1 cDNA in dyspedic myotubes [24]. Interestingly Du et al. [35]
showed that some RYR1 mutations within malignant hyperthermia domain 2 actually decrease
the caffeine sensitivity of the skeletal muscle RyR1, and postulate that amino acids within
residue 2163-2458 form a regulatory domain. Similarly, Jones et al. [36] have shown that
insertion of GFP after residues Thr2030 of the cardiac ryanodine receptor isoform, leads to
reduced activation by caffeine. In agreement with these reports, we found that the p.Arg2435Leu
substitution in RyR1 resulted in a reduced caffeine response compared to that obtained by 4-
chloro-m-cresol.
In conclusion this study shows that the homozygous p.Arg2435Leu mutation found in the
CCD patient is consistent with a channel defect of class 3, which leads to the functional
uncoupling of the RyR1 from the DHPR.
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Figure legends
Figure 1: Comparison of intracellular calcium homeostasis in myotubes from controls and
p.Arg2435Leu heterozygous and homozygous mutation-bearing individuals. Dose response
curves of fura-2 loaded myotubes to to  (A) caffeine and (B) 4-chloro-m-cresol. Myotubes were
individually stimulated by addition of the agonist in Krebs-Ringer buffer containing no added
Ca2+ and 100 µM La3+, thus the increase in [Ca2+]i represents only release of calcium from
intracellular stores. Curves show the caffeine, 4-chloro-m-cresol and caffeine dose dependent
changes in calcium, expressed as ∆ in fluorescence ratio (peak ratio 340/380 nm-resting ratio
340/380 nm). Each point represents the mean (±S.E.) of the ∆ fluorescence of measurements
performed on 5-20 different cells. (open circles, straight line, controls; half full box, dash-dot
line, heterozygous; closed boxes, dotted line, homozygous). Dose response curves were
generated using the Origin software. (C) Comparison of resting [Ca2+] (as fluorescent ratio) or
peak Ca2+ release after addition of KCl, caffeine and 4-chloro-m-cresol. Values represent the
mean± SEM of n number of different cells; *P<0.028, **P<0.015. Open bars= control, light grey
bars= heterozygous, dark grey bars= homozygous. For resting [Ca2+] n= 149,147 and 145; for
100 mM KCl n= 13, 9 and 7; for 10 mM caffeine n= 16,18 and 21; for 600 µM 4-cmc n= 23, 28
and 30 in control, heterozygous and homozygous mutation bearing cells, respectively.
Figure 2: Calcium and caffeine dependence of [3H]ryanodine binding to recombinant WT-
RyR1 and RyR1-Arg2435Leu mutant. (A) Specific [3H]ryanodine binding to crude membrane
fractions containing WT or mutant RyR1 was carried out as described in Methods in 0.25 M
KCl, 20 mM imidazole pH 7.0 containing, 5 mM Mg2+, 5 mM AMPPCP, 5 mM glutathione
(reduced), 1.5 nM [3H]ryanodine and the indicated concentrations of calcium.  (B) Caffeine
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dependence was determined at 0.15 µM free Ca2+.  Data represent the mean± SD of 3
experiments.
Figure 3: Single channel activities and conductances of WT and p.Arg2435Leu RyR1 ion
channels. (A) Traces represent single channel currents (openings shown as downward deflections
from the closed state, c) of WT RyR1 (left) and RyR1-Arg2435Leu (right) at -35 mV recorded in
symmetrical 250 mMKCl, 2 mMMgATPcis and indicated concentrations of free cis (cytosolic)
Ca2+. (B) Current voltage relationships of WT (solid symbols) and RyR1-Arg2435Leu (open
symbols) in symmetrical 250 mM KCl, 2 µM Ca2+ cis (circles) and following addition of 10 mM
trans Ca2+ (triangles). No significant differences were observed between WT (closed symbols)
and R2435L (open symbols) RyR1. One of four similar experiments is shown. (C) Ca2+
dependence of WT RyR1 and RyR1-Arg2435Leu single channel open probabilities (Po) in
symmetrical  250 mM KCl, 2 mM MgATP cis and indicated concentrations of free cis
(cytosolic) Ca2+. Data are the mean ± S.E. of 3-7 experiments.
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